UBS Group
RNTX

UBS Group’s Rein Therapeutics RNTX Stock Holding History

UBS Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33K Sell
1,024
-8,492
-89% -$10.5K ﹤0.01% 9551
2025
Q4 		$11K Buy
9,516
+9,433
+11,365% +$13K ﹤0.01% 8176
2025
Q3 		$95 Sell
83
-15,618
-99% -$19.8K ﹤0.01% 9928
2025
Q2 		$22K Buy
15,701
+12,721
+427% +$22.9K ﹤0.01% 8366
2025
Q1 		$5.28K Sell
2,980
-4,271
-59% -$8.96K ﹤0.01% 9016
2024
Q4 		$16.7K Buy
+7,251
New +$22K ﹤0.01% 7997
2024
Q3 		– Sell
-3,145
Closed -$8.71K – 10228
2024
Q2 		$8.71K Buy
3,145
+3,052
+3,282% +$12.5K ﹤0.01% 7786
2024
Q1 		$617 Sell
93
-2,051
-96% -$9.82K ﹤0.01% 8441
2023
Q4 		$6.54K Buy
+2,144
New +$4.18K ﹤0.01% 7694
2023
Q3 		– Sell
-1,357
Closed -$2.43K – 10076
2023
Q2 		$2.43K Buy
1,357
+1,257
+1,257% +$1.94K ﹤0.01% 7753
2023
Q1 		$124 Sell
100
-3,212
-97% -$6.88K ﹤0.01% 9203
2022
Q4 		$7.85K Buy
3,312
+3,212
+3,212% +$10.8K ﹤0.01% 8852
2022
Q3 		$0 Hold
100
– – ﹤0.01% 11055
2022
Q2 		$1K Sell
100
-456
-82% -$4.19K ﹤0.01% 10003
2022
Q1 		$6K Sell
556
-612
-52% -$5.54K ﹤0.01% 9012
2021
Q4 		$13K Buy
1,168
+784
+204% +$12.1K ﹤0.01% 8481
2021
Q3 		$8K Sell
384
-201
-34% -$4.4K ﹤0.01% 8236
2021
Q2 		$15K Buy
585
+476
+437% +$11.9K ﹤0.01% 7657
2021
Q1 		$3K Buy
+109
New +$3.73K ﹤0.01% 8540
2020
Q4 		– Sell
-264
Closed -$7K – 8843
2020
Q3 		$7K Sell
264
-768
-74% -$18.1K ﹤0.01% 7150
2020
Q2 		$24K Buy
+1,032
New +$16.8K ﹤0.01% 6443
2020
Q1 		– Sell
-167
Closed -$2K – 8506
2019
Q4 		$2K Buy
+167
New +$1.65K ﹤0.01% 7860
2019
Q2 		– Sell
-100
Closed -$4K – 8220
2019
Q1 		$4K Buy
+100
New +$3.12K ﹤0.01% 7277
2018
Q4 		– Sell
-218
Closed -$12K – 8365
2018
Q3 		$12K Buy
218
+215
+7,167% +$14.5K ﹤0.01% 7082
2018
Q2 		$0 Buy
+3
New +$340 ﹤0.01% 8319
2018
Q1 		– Sell
-88
Closed -$18K – 8230
2017
Q4 		$18K Buy
88
+30
+52% +$7.19K ﹤0.01% 6638
2017
Q3 		$16K Buy
+58
New +$14.5K ﹤0.01% 6613

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

UBS Group's RNTX Position: Q1 2026 in Review

UBS Group reduced its Rein Therapeutics (RNTX) stake by 89% in Q1 2026, selling an estimated $10.5K and leaving 1,024 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #9551.

UBS Group first reported a position in RNTX in Q3 2017 and has held it in 27 quarters since. The position peaked at $24K in Q2 2020. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • UBS Group held 1,024 shares of Rein Therapeutics worth $1.33K as of Q1 2026.
  • UBS Group sold 8,492 Rein Therapeutics shares in Q1 2026, an estimated $10.5K.
  • Rein Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9551 holding.
  • UBS Group first reported a position in Rein Therapeutics in Q3 2017 and has held it in 27 quarters since.
  • UBS Group's Rein Therapeutics position peaked at $24K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.